Lumakras (sotorasib tablets - Amgen) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has KRAS G12C-mutated disease, as determined by an approved test
• Medication is used as subsequent therapy

Approval duration

1 year